Articles

BCL6 inhibition ameliorates ruxolitinib resistance in CRLF2-rearranged acute lymphoblastic leukemia

Department of Biochemistry, Aichi Medical University, School of Medicine, Nagakute, Aichi
Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi
Division of Hematology/Oncology, Kanagawa Children’s Medical Center, Yokohama, Kanagawa
Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi
Department of Pediatrics, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi
Department of Pediatrics, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi
Department of Hematology, Fujita Health University School of Medicine, Toyoake, Aichi
Department of Biochemistry, Aichi Medical University, School of Medicine, Nagakute, Aichi
Department of Biochemistry, Aichi Medical University, School of Medicine, Nagakute, Aichi
Department of Biochemistry, Aichi Medical University, School of Medicine, Nagakute, Aichi
Department of Biochemistry, Aichi Medical University, School of Medicine, Nagakute, Aichi
Department of Biochemistry, Aichi Medical University, School of Medicine, Nagakute, Aichi
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi
Department of Integrated Health Sciences, Division of Cellular and Genetic Sciences, Nagoya University Graduate School of Medicine, Nagoya, Aichi
Haematologica Early view Aug 25, 2022 https://doi.org/10.3324/haematol.2022.280879